A Genome‐wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites

Turner, Richard M ORCID: 0000-0002-7315-679X, Fontana, Vanessa ORCID: 0000-0002-0146-9113, Zhang, Jieying E ORCID: 0000-0003-1813-2207, Carr, Daniel, Yin, Peng, FitzGerald, Richard, Morris, Andrew P and Pirmohamed, Munir ORCID: 0000-0002-7534-7266
(2020) A Genome‐wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites. Clinical Pharmacology and Therapeutics, 108 (2). pp. 287-297.

[img] Text
Turner 2020 ATV GWAS.pdf - Published version

Download (1MB) | Preview


Atorvastatin (ATV) is frequently prescribed and generally well tolerated, but can lead to myotoxicity, especially at higher doses. A genome‐wide association study of circulating levels of ATV, 2‐hydroxy (2‐OH) ATV, ATV lactone (ATV L), and 2‐OH ATV L was performed in 590 patients who had been hospitalized with a non‐ST elevation acute coronary syndrome 1 month earlier and were on high‐dose ATV (80 mg or 40 mg daily). The UGT1A locus (lead single nucleotide polymorphism, rs887829) was strongly associated with both increased 2‐OH ATV/ATV (P = 7.25 × 10−16) and 2‐OH ATV L/ATV L (P = 3.95 × 10−15) metabolic ratios. Moreover, rs45446698, which tags CYP3A7*1C, was nominally associated with increased 2‐OH ATV/ATV (P = 6.18 × 10−7), and SLCO1B1 rs4149056 with increased ATV (P = 2.21 × 10−6) and 2‐OH ATV (P = 1.09 × 10−6) levels. In a subset of these patients whose levels of ATV and metabolites had also been measured at 12 months after hospitalization (n = 149), all of these associations remained, except for 2‐OH ATV and rs4149056 (P = 0.057). Clinically, rs4149056 was associated with increased muscular symptoms (odds ratio (OR) 3.97; 95% confidence interval (CI) 1.29–12.27; P = 0.016) and ATV intolerance (OR 1.55; 95% CI 1.09–2.19; P = 0.014) in patients (n = 870) primarily discharged on high‐dose ATV. In summary, both novel and recognized genetic associations have been identified with circulating levels of ATV and its major metabolites. Further study is warranted to determine the clinical utility of genotyping rs4149056 in patients on high‐dose ATV.

Item Type: Article
Uncontrolled Keywords: Humans, Muscular Diseases, Lactones, Glucuronosyltransferase, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Risk Assessment, Risk Factors, Prospective Studies, Pharmacogenetics, Biotransformation, Polymorphism, Single Nucleotide, Middle Aged, Female, Male, Cytochrome P-450 CYP3A, Genome-Wide Association Study, United Kingdom, Pharmacogenomic Variants, Atorvastatin, Liver-Specific Organic Anion Transporter 1
Depositing User: Symplectic Admin
Date Deposited: 24 Apr 2020 14:42
Last Modified: 18 Jan 2023 23:54
DOI: 10.1002/cpt.1820
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3084386